Study of asthma prevention and treatment with the administration of viable and heat-killed Saccharomyces cerevisiae in a murine model of allergic asthma

• Grant number: 10/20600-4
• Support Opportunities: Research Grants - Young Investigators Grants
• Start date: September 01, 2011
• End date: August 31, 2016
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Marcos de Carvalho Borges
• Grantee: Marcos de Carvalho Borges
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Associated researchers: Elcio dos Santos Oliveira Vianna ; Vânia Luiza Deperon Bonato
• Associated scholarship(s): 15/24223-4 - Anti-inflammatory mechanisms effect of Saccharomyces cerevisiae strain UFMG 905 in animal model, BP.IC; 14/07616-0 - Study of asthma treatment with the administration of Pyrostegia venusta extract in a mouse model of allergic asthma, BP.MS; 13/02209-4 - Study of asthma prevention with the administration of viable Saccharomyces cerevisiae in a murine model of allergic asthma, BP.MS

Abstract

Background: The prevalence of asthma has increased in children and in communities that adopt a Western lifestyle and become more urbanized. The hygiene hypothesis suggests that exposure to infections early in life can reduce the risk of asthma and other allergic diseases. Probiotics are live microorganisms that confer a health benefit to the host. Treatment with Saccharomyces cerevisiae protected mice against intestinal infections, prevented bacterial translocation and increased IL-10 production. Administration of Beta-1-3 Glucan, a polysaccharide extracted from fungi and yeasts such as S. cerevisiae, reduced symptoms of allergic rhinitis and increased IL-10 production in asthmatic children. There is no study of S. cerevisiae in the prevention or treatment of asthma. Objective: Evaluate the effects of viable and heat-killed S. cerevisiae oral administration in prevention and treatment of asthma and the mechanisms involved. Methods: Balb/c mice will be used in the study. Initially, a dose-response curve will be realized to determine the probiotic dose. Viable and heat-killed S. cerevisiae will be administered before and after sensitization with ovalbumin. After sensitization and challenge, mice will be ventilated and in vivo measurements of bronchial hyperresponsiveness will be realized. Bronchoalveolar lavage will be collected to quantify total and differential cell counts and cytokine levels by ELISA (IL-4, IL-5, IL-10, IL-13, IFN-gamma, TNF-alpha and TGF-beta). Histochemistry will be performed in the lungs to quantify inflammation, collagen and mucus. Real time PCR will be realized in lung tissue to measure inflammatory cytokine, such as IL-4, IL-5, IL-10, IL-13, IFN-gamma, TNF-alpha and TGF-beta. Flow cytometry will be realized to quantify regulatory T lymphocytes. Regulatory T lymphocytes will be isolated, cultured and there function will be assessed by proliferation assay and cytokine measurement of cell culture supernatant. Significance: Considering the hygiene hypothesis, the mechanisms of action and safety of probiotics, it is expected that administration of Saccharomyces cerevisiae will reduce airway inflammation, hyperresponsiveness and remodeling, and could be considered for asthma treatment. (AU)

Scientific publications

(6)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

BALESTRA, ANDIAMIRA CAGNONI; SANDY, CAMILA MIRA; RAMALHO, FERNANDO; JORDAO JUNIOR, ALCEU AFONSO; TALEB CONTINI, SILVIA HELENA; CREVELIN, EDUARDO JOSE; CARMONA, FABIO; PEREIRA, ANA MARIA S.; BORGES, MARCOS C.. Aqueous Pyrostegia venusta (Ker Gawl.) Miers extract attenuates allergen-induced asthma in a mouse model via an antioxidant mechanism. JOURNAL OF ASTHMA, v. 58, n. 6, FEB 2020. (10/20600-4, 14/07616-0)

FONSECA, VANESSA M. B.; MILANI, THAMIRES M. S.; PRADO, RAFAEL; BONATO, VANIA L. D.; RAMOS, SIMONE G.; MARTINS, FLAVIANO S.; VIANNA, ELCIO O.; BORGES, MARCOS DE C.. Oral administration of Saccharomyces cerevisiae UFMG A-905 prevents allergic asthma in mice. Respirology, v. 22, n. 5, p. 905-912, JUL 2017. (10/20600-4)

MASSIS, LILIANA M.; ASSIS-MARQUES, MARIANA A.; CASTANHEIRA, FERNANDA V. S.; CAPOBIANCO, YASMIN J.; BALESTRA, ANDIAMIRA C.; ESCOLL, PEDRO; WOOD, REBECCA E.; MANIN, GRAZIELE Z.; CORREA, VANI M. A.; ALVES-FILHO, JOSE C.; et al. Legionella longbeachae Is Immunologically Silent and Highly Virulent In Vivo. Journal of Infectious Diseases, v. 215, n. 3, p. 440-451, FEB 1 2017. (13/08216-2, 14/04684-4, 10/20600-4, 14/50268-2, 12/09363-6)

AMORIM, JOWANKA; BORGES, MARCOS DE CARVALHO; FABRO, ALEXANDRE TODOROVIC; TALEB CONTINI, SILVIA HELENA; VALDEVITE, MAYARA; SOARES PEREIRA, ANA MARIA; CARMONA, FABIO. The ethanolic extract from Erythrina mulungu Benth. flowers attenuates allergic airway inflammation and hyperresponsiveness in a murine model of asthma. Journal of Ethnopharmacology, v. 242, OCT 5 2019. (10/20600-4)

MILANI, THAMIRES M. S.; SANDY, CAMILA M.; CARVALHO THIERS CALAZANS, ANA PAULA; SILVA, ROSANA Q.; FONSECA, VANESSA M. B.; MARTINS, FLAVIANO S.; BORGES, MARCOS C.. Dose-Response Effect of Saccharomyces cerevisiae UFMG A-905 on the Prevention of Asthma in an Animal Model. PROBIOTICS AND ANTIMICROBIAL PROTEINS, v. N/A, p. 9-pg., 2022-11-29. (10/20600-4)

GUIMARAES, CAMILA CARLA; SANDY, CAMILA MIRA; FIGUEIRA, REBECA; GONCALVES, MIRANI DA ROCHA; CREVELIN, EDUARDO JOSE; CARDOSO, PEDRO HENRIQUE; FABRO, ALEXANDRE TODOROVIC; CARMONA, FABIO; BORGES, MARCOS DE CARVALHO; SOARES PEREIRA, ANA MARIA. Anti-asthmatic activity of standardized hydro-ethanolic and aqueous extracts of Stachytarpheta cayennensis (Rich.) Vahl in a murine model. Journal of Ethnopharmacology, v. 302, p. 11-pg., 2023-02-10. (10/20600-4)